Company: TAK
Filing Date: 2025-10-30
Form Type: 6-K
Source: 0001395064-25-000152
Chunk: 27

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-10-30
Form: 6-K
Chunk 27
---
 |         — |     |                |   |     |                                              |    37,143 |     |        |     |     |    37,143 |
| Exercise of share-based awards             |     |                                              |         |     |         |         |     |                                                 |      |     |                            |         — |     |                |   |     |                                              |   -36,129 |     |        |     |     |   -36,129 |
| Total transactions with owners             |     |                                              |       — |     |         |       — |     |                                                 | -703 |     |                            |      -840 |     |                | — |     |                                              |  -112,428 |     |        |   — |     |  -112,428 |
| As of September 30, 2024                   |     |                                              | -37,592 |     |         | -10,274 |     |                                                 |    — |     |                            | 2,081,095 |     |                | — |     |                                              | 6,920,754 |     |        | 843 |     | 6,921,597 |

<div align='center'>19</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Six-month

Period Ended September 30, 2025 (Consolidated)

Six-month period ended September 30, 2025 (From April 1 to September 30, 2025)

|                                                                             |     |                                              |     | JPY (millions) |           |     |         |     |                                                                                                     |           |     |          |     |         |     |          |     |           |     |                            |     |           |     |        |
|                                                                             |     | Equity attributable to owners of the Company |     |                |           |     |         |     |                                                                                                     |           |     |          |     |         |     |          |     |           |     |                            |     |           |     |        |
|                                                                             |     | Share                                        
 capital                                      |     |                |           |     | Share   
 premium |     |                                                                                                     |           |     | Treasury 
 shares   |     |         |     | Retained 
 earnings |     |           |     | Other components of equity |     |           |     |        |
|                                                                             |     |                                              |     | Exchange       
 differences